Clinical Trials
5
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Invitae Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT06043921
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
- Conditions
- Prostate Cancer
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Invitae Corporation
- Target Recruit Count
- 1000
- Registration Number
- NCT05447637
- Locations
- 🇺🇸
Genesis Healthcare Partners, San Diego, California, United States
🇺🇸Invitae, San Francisco, California, United States
🇺🇸Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States
Universal Germline Testing in the Community
- Conditions
- Solid TumorSolid Tumor, AdultCancer
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Invitae Corporation
- Target Recruit Count
- 1000
- Registration Number
- NCT05416710
- Locations
- 🇺🇸
Carolina Blood and Cancer Care Associates, PA', Rock Hill, South Carolina, United States
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
- Conditions
- Pancreatic CancerResectable Pancreatic CancerPancreatic Adenocarcinoma
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Invitae Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT05380557
- Locations
- 🇺🇸
Invitae SF, San Francisco, California, United States
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
- Conditions
- Non Small Cell Lung CancerCancerSolid TumorColorectal CancerBladder Cancer
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Invitae Corporation
- Target Recruit Count
- 400
- Registration Number
- NCT05219734
- Locations
- 🇺🇸
Columbus Regional Health, Columbus, Indiana, United States
🇺🇸Onslow Radiation, Jacksonville, North Carolina, United States
News
Citizen Health Raises $30M Series A to Develop AI Advocate for Rare Disease Patients
Citizen Health secured $30 million in Series A funding led by 8VC to develop an AI Advocate platform for rare disease patients, bringing total funding to $44 million since December 2023.
Genetic Testing Improves Outcomes in Epilepsy Patients by Guiding Therapy
A new study reveals that genetic testing in epilepsy patients leads to changes in clinical management in approximately half of the cases.